Vaccine candidates for hantavirus remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with DNA platforms showing neutralizing antibodies in small human studies yet requiring multiple doses and further efficacy data. Recent 2026 outbreak interest has spurred mRNA and viral-vector efforts, including collaborations exploring stabilized glycoproteins, but regulatory approval pathways and limited commercial incentives for this sporadic rodent-borne disease make widespread availability by year-end improbable. Historical precedents indicate 5–10 years for full licensure without emergency acceleration. A sudden large-scale funding initiative or breakthrough Phase 3 results could narrow the timeline, though current model consensus and trial schedules point strongly against it.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$120,378 Vol.
$120,378 Vol.
Dec 31, 2026
$120,378 Vol.
$120,378 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with DNA platforms showing neutralizing antibodies in small human studies yet requiring multiple doses and further efficacy data. Recent 2026 outbreak interest has spurred mRNA and viral-vector efforts, including collaborations exploring stabilized glycoproteins, but regulatory approval pathways and limited commercial incentives for this sporadic rodent-borne disease make widespread availability by year-end improbable. Historical precedents indicate 5–10 years for full licensure without emergency acceleration. A sudden large-scale funding initiative or breakthrough Phase 3 results could narrow the timeline, though current model consensus and trial schedules point strongly against it.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$120,378End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with DNA platforms showing neutralizing antibodies in small human studies yet requiring multiple doses and further efficacy data. Recent 2026 outbreak interest has spurred mRNA and viral-vector efforts, including collaborations exploring stabilized glycoproteins, but regulatory approval pathways and limited commercial incentives for this sporadic rodent-borne disease make widespread availability by year-end improbable. Historical precedents indicate 5–10 years for full licensure without emergency acceleration. A sudden large-scale funding initiative or breakthrough Phase 3 results could narrow the timeline, though current model consensus and trial schedules point strongly against it.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$120,378End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Vaccine candidates for hantavirus remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with DNA platforms showing neutralizing antibodies in small human studies yet requiring multiple doses and further efficacy data. Recent 2026 outbreak interest has spurred mRNA and viral-vector efforts, including collaborations exploring stabilized glycoproteins, but regulatory approval pathways and limited commercial incentives for this sporadic rodent-borne disease make widespread availability by year-end improbable. Historical precedents indicate 5–10 years for full licensure without emergency acceleration. A sudden large-scale funding initiative or breakthrough Phase 3 results could narrow the timeline, though current model consensus and trial schedules point strongly against it.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions